Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

What this study is about

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

Who can join (things the study team will check)

✅ You may be able to join if…

• Are between ≥ 18 years and ≤ 85 years at the signing of informed consent
• Have a history of chronic HFrEF, defined as requiring treatment for HF for a minimum of 3 months prior to screening
• Are receiving oral loop diuretics on a regular schedule
• Patients without AFF on screening ECG:
  • LVEF < 30% within 6 months of screening
  • Elevated N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) ≥ 1000 pg/mL (BNP ≥ 300 pg/mL)
• Patients with AFF on screening ECG:
  • LVEF < 25% within 6 months of screening
  • Elevated N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) ≥ 3000 pg/mL (BNP ≥ 900 pg/mL)
  • Not currently taking digoxin
• Meet one of the following criteria for a recent HF event:
  • Are currently hospitalized with the primary reason of HF
  • Had an HF event (as defined in the primary endpoint) within 12 months prior to screening. For the purposes of a qualifying HF event, subcutaneous furosemide will be treated as equivalent to intravenous furosemide Or
  • Had outpatient escalation of oral diuretics due to worsening signs and symptoms of heart failure plus one of two additional criteria sustained for at least 1 week: (1) at least 50% or 1.5-fold increase in daily loop-diuretic-equivalent dose; (2) the addition of a new diuretic class to a loop diuretic.
• Are established on regional standard-of-care HF therapies for at least 30 days prior to screening
• Systolic blood pressure ≤ 140 mmHg

🚫 You may not be able to join if…

• Have AFF on the screening ECG and are currently taking digoxin
• Have had any event or procedure that may have resulted in a change in ejection fraction, including, but not limited to, acute coronary syndrome and/or any coronary revascularization, cardiac surgery, valve surgery, any coronary revascularization, and/or cardiac resynchronization, or cardiac contractility modulation therapy within 3 months of screening
• Are admitted to a long-term care facility or hospice
• Have a projected survival of < 12 months due to non-cardiovascular causes based on clinical judgment
• Are receiving intravenous inotropes or intravenous vasopressors ≤ 3 days prior to screening
• Are receiving mechanical hemodynamic support or mechanical ventilation ≤ 7 days prior to screening
• Are receiving intravenous diuretics, intravenous vasodilators, or supplemental oxygen therapy ≤ 12 hours prior to screening (except for nocturnal supplemental oxygen for sleep apnea or heart failure)
• Have an estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73m2 or receiving dialysis at screening
• Have previously had a solid organ transplant
• Are receiving treatment in another investigational device or drug study or are within 30 days of ending such investigational treatment at screening
• Have received omecamtiv mecarbil in a previous clinical trial
• Are pregnant or planning pregnancy during the study period, or planning to breastfeed during treatment with IP or within 5 days after the end of treatment with IP
• Have primary infiltrative cardiomyopathy (e.g. cardiac amyloidosis) or severe stenotic valvular disease

Where this trial is running

• Advanced Cardiovascular, LLC, Alexander City, Alabama, United States
• University of Alabama at Birmingham, Birmingham, Alabama, United States
• Pima Heart and Vascular Clinical Research, Tucson, Arizona, United States
• National Heart Institute, Beverly Hills, California, United States
• UC San Diego Health - Sulpizio Cardiovascular Center, La Jolla, California, United States
• Nutrition Research Center (SPH), Loma Linda, California, United States
• Keck Medical Center of USC (outpatient clinic), Los Angeles, California, United States
• UCLA Medical Center Cardiovascular Clinic, Los Angeles, California, United States
• University of California, Irvine Medical Center, Orange, California, United States
• Sutter Institute for Medical Research (SIMR), Sacramento, California, United States
• UC Davis Health, Sacramento, California, United States
• San Diego Cardiac Center, San Diego, California, United States

+ 179 more sites.

Who to contact

Cytokinetics MD · (650) 624-2929 · medicalaffairs@cytokinetics.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06736574.